FORXIGA® (dapagliflozin)

FORXIGA® (dapagliflozin) is a highly selective SGLT2 inhibitor for type 2 diabetes mellitus, with 4-year safety and efficacy data, that removes glucose and its associated calories via the kidney.1

FORXIGA®(dapagliflozin) in secondary care

Start change earlier for your patients

Consider FORXIGA® (dapagliflozin) ahead of a GLP-1 for:

  • A numerically similar reduction in HbA1c to once-weekly exenatide, a GLP-1 (in an RCT)10
  • The secondary benefit of weight loss, proportional to patient BMI1,4
  • Simple dosing1

RCT randomised controlled trial.

What could FORXIGA® (dapagliflozin) do for your patients ahead of a GLP-1 and across the treatment pathway?

In a Phase 3 trial, FORXIGA®(dapagliflozin), once weekly exenatide (a GLP-1) and a combination of FORXIGA® (dapagliflozin) + exenatide all showed reductions in weight at 28 weeks10

Reduction from baseline in weight at week 28 with FORXIGA®(dapagliflozin) , exenatide and FORXIGA® (dapagliflozin) + exenatide10

Reduction in weight from baseline at week 28 with FORXIGA®, exenatide and FORXIGA® + exenatide
Reduction in weight from baseline at week 28 with FORXIGA®, exenatide and FORXIGA® + exenatide

Adapted from Frias JP et al. 2016

*Neither FORXIGA® (dapagliflozin) or exenatide are indicated for weight loss. Weight change was a secondary endpoint in clinical trials.1

Statistical significance for the between-group difference was not tested.10

GLP-1, glucagon-like peptide 1; LS, least-squares; CI, confidence interval.

FORXIGA®(dapagliflozin) can be used in combination with insulin, with data available up to 104 weeks32

Significant reductions in weight from baseline over 104 weeks with FORXIGA® (dapagliflozin) 10 mg plus insulin32

Reduction in weight from baseline over 104 weeks with FORXIGA® plus insulin
Reduction in weight from baseline over 104 weeks with FORXIGA® plus insulin

Adapted from Wilding JP et al. 2014

*Neither FORXIGA® (dapagliflozin) or exenatide are indicated for weight loss. Weight change was a secondary endpoint in clinical trials.1
CI, confidence interval; ST, shorter therapy; LT, longer therapy.